A PHASE 2, TWO-STAGE, STUDY OF MIRVETUXIMAB SORAVTANSINE (IMGN853) IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH MICROSATELLITE STABLE (MSS) RECURRENT OR PERSISTENT ENDOMETRIAL CANCER (EC)

被引：1
|
作者：
Porter, Rebecca [1 ]
Tayob, Nabihah [2 ]
Polak, Madeline [1 ]
Sawyer, Hannah [1 ]
Gardner, Jeanette [1 ]
Campos, Susana [1 ]
Krasner, Carolyn [1 ]
Lee, Elizabeth [1 ]
Liu, Joyce [3 ]
Stover, Elizabeth [1 ]
Veneris, Jennifer [4 ]
Wright, Alexi [1 ]
Matulonis, Ursula [3 ]
Konstantinopoulos, Panagiotis [1 ]
机构：
[1] Dana Farber Canc Inst, Div Gynecol Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA
[4] Dana Farber Canc Inst, Div Gynecol Oncol, Waltham, MA USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷
关键词：
D O I：
10.1136/ijgc-2022-igcs.524
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TP015/#156
引用
收藏
页码：A229 / A230
页数：2
相关论文
共 50 条
  • [1] A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer
    Porter, Rebecca L.
    Xiong, Niya
    Tayob, Nabihah
    Polak, Madeline
    Sawyer, Hannah
    Hayes, Martin
    Gardner, Jeanette
    Campos, Susana
    Horowitz, Neil
    Krasner, Carolyn
    Lee, Elizabeth K.
    Liu, Joyce F.
    Stover, Elizabeth H.
    Veneris, Jennifer
    Wright, Alexi A.
    Matulonis, Ursula A.
    Konstantinopoulos, Panagiotis
    CANCER RESEARCH, 2024, 84 (07)
  • [2] A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) endometrial cancer (EC).
    Porter, Rebecca L.
    Veneris, Jennifer Taylor
    Tayob, Nabihah
    West, Gabriela
    Polak, Madeline
    Gardner, Jeanette
    Campos, Susana M.
    Krasner, Carolyn N.
    Lee, Elizabeth Katherine
    Liu, Joyce F.
    Stover, Elizabeth
    Wright, Alexi A.
    Matulonis, Ursula A.
    Konstantinopoulos, Panagiotis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC).
    Cristea, Mihaela C.
    Frankel, Paul Henry
    Synold, Timothy W.
    Mortimer, Joanne E.
    Stewart, Daphne B.
    Wang, Edward Wenge
    Jung, Alex
    Wilczynski, Sharon P.
    Konecny, Gottfried E.
    Parungao, Dia
    Eng, Melissa
    Kilpatrick, Lindsay
    Chen, Yi-Jen
    Glaser, Scott
    Han, Ernest Soyoung
    Dellinger, Thanh Hue
    Hakim, Amy
    Lee, Stephen
    Morgan, Robert
    Wakabayashi, Mark Tsuneo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC).
    Konstantinopoulos, Panagiotis A.
    Liu, Joyce F.
    Luo, Weixiu
    Krasner, Carolyn N.
    Ishizuka, Jeffrey Joseph
    Gockley, Allison Ann
    Buss, Mary K.
    Campos, Susana M.
    Stover, Elizabeth
    Wright, Alexi A.
    Growdon, Whitfield Board
    Curtis, Jennifer
    Peralta, Ariana
    Basada, Patrice
    Quinn, Roxanne
    Gray, Kathryn P.
    Penson, Richard T.
    Cannistra, Stephen A.
    Fleming, Gini F.
    Matulonis, Ursula A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Phase II, two-stage study of avelumab in patients with microsatellite stable (MSS), microsatellite instable (MSI) and polymerase epsilon (POLE) mutated recurrent or persistent endometrial cancer
    Konstantinopoulos, P. A.
    Liu, J. F.
    Barry, W.
    Krasner, C.
    Buss, M. K.
    Birrer, M. J.
    Farooq, S.
    Campos, S. M.
    Stover, E.
    Schumer, S.
    Wright, A. A.
    Dizon, D. S.
    Luo, W.
    Penson, R. T.
    Cannistra, S. A.
    Fleming, G. F.
    Matulonis, U. A.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 24 - 25
  • [6] Phase 1 Dose-Escalation Study of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor α-Targeting Antibody-Drug Conjugate, in Patients With Solid Tumors
    Moore, Kathleen N.
    Borghaei, Hossein
    O'Malley, David M.
    Jeong, Woondong
    Seward, Shelly M.
    Bauer, Todd M.
    Perez, Raymond P.
    Matulonis, Ursula A.
    Running, Kelli L.
    Zhang, Xiaoyan
    Ponte, Jose F.
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    CANCER, 2017, 123 (16) : 3080 - 3087
  • [7] A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.
    Trillsch, Fabian
    Schochter, Fabienne
    Park-Simon, Tjoung-Won
    Reuss, Alexander
    Fehm, Tanja N.
    Wimberger, Pauline
    Bronger, Holger
    Schmalfeldt, Barbara
    Sehouli, Jalid
    Marme, Frederik
    Heitz, Florian
    Mahner, Sven
    Fredrich, Michaela
    Barth, Stefanie
    Stec, James Joseph
    Method, Michael W.
    Harter, Philipp
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and POLE-mutated recurrent or persistent endometrial cancer.
    Konstantinopoulos, Panagiotis A.
    Liu, Joyce F.
    Barry, William Thomas
    Krasner, Carolyn N.
    Buss, Mary K.
    Birrer, Michael J.
    Farooq, Sarah
    Campos, Susana M.
    Stover, Elizabeth
    Schumer, Susan
    Wright, Alexi A.
    Curtis, Jennifer
    Peralta, Ariana
    Whalen, Christin
    Dizon, Don S.
    Penson, Richard T.
    Cannistra, Stephen A.
    Fleming, Gini F.
    Matulonis, Ursula A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
    Lee, Elizabeth Katherine
    Xiong, Niya
    Tayob, Nabihah
    Krasner, Carolyn N.
    Buss, Mary K.
    Campos, Susana M.
    Wright, Alexi A.
    Liu, Joyce F.
    Shea, Meghan
    Yeku, Oladapo O.
    Castro, Cesar Martin
    Porter, Rebecca L.
    Stover, Elizabeth
    Bouberhan, Sara
    Moroney, John William
    Cannistra, Stephen A.
    Penson, Richard T.
    Fleming, Gini F.
    Matulonis, Ursula A.
    Konstantinopoulos, Panagiotis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair-proficient (MMR-P) recurrent or persistent endometrial cancer (EC)
    Lee, Elizabeth Katherine
    Xiong, Niya
    Cheng, SuChun
    Polak, Madeline
    Krasner, Carolyn N.
    Campos, Susana M.
    Wright, Alexi A.
    Liu, Joyce F.
    Shea, Meghan
    Yeku, Oladapo O.
    Castro, Cesar Martin
    Porter, Rebecca L.
    Stover, Elizabeth
    Bouberhan, Sara
    Moroney, John William
    Penson, Richard T.
    Fleming, Gini F.
    Matulonis, Ursula A.
    Konstantinopoulos, Panagiotis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345